Added to YB: 2024-08-16
Pitch date: 2024-08-15
ILMN [neutral]
Illumina, Inc.
+3.75%
current return
Author Info
Two Natural Capital writes about markets, particularly focused on life sciences/biotech. Sign up for the newsletter.
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$18.4B
Pitch Price
$130.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
15.81
P/E
27.05
EV/Sales
4.60
Sector
Life Sciences Tools and Services
Category
turnaround
Illumina and Cannibalizing Your Customers
ILMN: NGS leader facing challenges. Dominant position w/ 25k+ instruments, strong customer lock-in. New NovaSeqX launch impacting margins/revenue. Competition rising (BGI, Element, Ultima). China struggles. Regulatory scrutiny limits M&A. Still best-in-class but commoditization risk. Bull case: single-cell/spatial analysis demand. Bear case: price pressure, competition. Key metrics: instrument installs, consumable revenue, margins.
Read full article (7 min)